Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

INTERACT Supports Updated NCCN Guidelines that Expand Access to Appropriate Hereditary Cancer Genetic Testing

prnewswire.com
AMGN While not directly mentioned, Amgen is a major player in the biotech and healthcare sector, which is indirectly supported by the expansion of genetic testing guidelines for hereditary cancers. The article focuses on the guidelines themselves rather than specific company products. ILMN Illumina is listed as a member of the INTERACT coalition, which supports updated NCCN guidelines. These updates expand access to genetic testing, a core business for Illumina, suggesting potential for increased demand for their sequencing and analysis technologies. MYGN Myriad Genetics is a member of the INTERACT coalition supporting the NCCN guideline updates. The expansion of hereditary cancer genetic testing directly benefits Myriad's business, as it increases the patient pool eligible for their genetic testing services. NTRA Natera is listed as a member of the INTERACT coalition. The article's focus on expanding access to hereditary cancer genetic testing is positive for Natera, as it aligns with and likely drives demand for their genetic diagnostic solutions. DGX Quest Diagnostics is part of the INTERACT coalition, which supports the updated NCCN guidelines. The expansion of genetic testing access is beneficial for Quest's diagnostic services, potentially leading to increased utilization of their hereditary cancer testing capabilities.

INTERACT Supports Updated NCCN Guidelines that Expand Access to Appropriate Hereditary Cancer Genetic Testing SAN DIEGO, Sept. 14, 2026 /PRNewswire/ -- The Inter-Organization Cancer Genetics Clinical Evidence Coalition (INTERACT) applauds the National Comprehensive Cancer Network (NCCN) for its newest updates to the Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, Esophageal, and Gastric cancers guidelines, and the Neuroendocrine and Adrenal Tumors guidelines. Together, these updates represent a significant advancement in the identification of individuals with hereditary cancer risk and expand access to evidence-based genetic testing for patients and families impacted by colorectal, endometrial, esophageal, gastric, neuroendocrine, and adrenal cancers.

Hereditary cancer genetic testing plays a critical role in identifying individuals with inherited cancer predisposition syndromes. When risk is identified, patients and their families can pursue tailored surveillance, preventive options, and, in some cases, targeted therapies that significantly improve clinical outcomes.

By broadening recommendations for hereditary cancer assessment across these disease areas, the NCCN continues to help more patients and families access the genetic information needed to guide the most clinically- and cost-effective treatment decisions, cancer surveillance, and preventive care.

Key updates in the new guidelines include:

NCCN Guidelines are widely recognized as the gold standard for clinical decision-making in oncology. Developed by multidisciplinary panels of experts, these recommendations guide patient care, inform clinical workflows, and shape insurance coverage decisions across the United States.

"We are encouraged to see NCCN continue to evolve its guidelines to reflect the growing body of evidence supporting broader access to hereditary cancer genetic testing," said Lisa Schlager, Vice President of Public Policy for FORCE: Facing Our Risk of Cancer Empowered. "These updates, particularly the inclusion of expanded considerations for esophageal and gastric cancers, will help ensure more at-risk individuals are identified earlier and connected with appropriate preventive and treatment strategies."

"These updates will help more patients and their families learn they carry hereditary cancer risk before it's too late to act on it," said Robin Dubin, Executive Director of AliveandKick'n. "Earlier, broader genetic testing means earlier surveillance and prevention, and for the families we serve, that can be the difference between catching cancer early and facing a late-stage diagnosis. We're grateful NCCN continues to follow the evidence."

ABOUT INTERACT

INTERACT is a coalition dedicated to advancing evidence-based access to genetic testing for individuals with or at risk of hereditary cancers. By supporting updates such as these, the coalition aims to improve outcomes through earlier detection, targeted interventions, and informed family risk assessment.

The INTERACT coalition includes leading industry organizations—Ambry Genetics, Illumina, Myriad Genetics, Natera, Quest Diagnostics, and My Gene Counsel—as well as patient advocacy groups including AlivendKick'n, FORCE: Facing Our Risk of Cancer Empowered, the Ovarian Cancer Research Alliance, Let's Win Pancreatic Cancer, My Faulty Gene, Colon Cancer Coalition, TOUCH4LIFE ®, and ZERO Prostate Cancer. Together, these organizations advocate for equitable access to genetic testing and work to advance clinical guidelines that reflect current scientific evidence.

CONTACTS

You can contact INTERACT here.

SOURCE INTERACT Coalition